London Daily

Focus on the big picture.
Thursday, Jul 10, 2025

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

A new study describes the results of the safety and efficacy phase trials of a new COVID-19 vaccine from Cuba.

Study findings
Vaccines are a high-priority public health intervention; however, the success of the vaccination program depends on the speed and coverage of the rollout.

SOBERANA 02 is the first conjugated vaccine to be developed against SARS-CoV-2. The vaccine uses the recombinant receptor-binding domain (RBD) of the viral spike protein, chemically attached to the tetanus toxoid antigen in a molar ratio of 6:1 and adsorbed on 500 micrograms (µg) of alumina. Conversely, SOBERANA Plus contains dimeric RBD 50 µg, adsorbed on 1,250 µg alumina, having been developed as a “universal booster.”

With this, SOBERANA 02 joins other conjugated vaccines, such as the protein-polysaccharide conjugated vaccine against Hemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae.

With the current experimental vaccine, two doses have been found to elicit neutralizing antibodies, along with both memory B- and T-cells, secreting interferon-gamma (IFN-γ) as well as showing a T-helper cell type 1 (Th1) profile of immunity.

This vaccine could also be used as a heterologous third booster dose to enhance the level of neutralizing anti-RBD antibodies. Following successful Phase 1 and 2a trials, the Phase 3 trial was launched to assess the efficacy and safety profile of two usage patterns of SOBERANA, which include a two-dose regimen of SOBERANA 02, and evaluate this regimen when combined with the third dose of SOBERANA Plus.

The participants of the current study were all healthy adults from different parts of Havana, Cuba. Each participant was assigned in a randomized double-blinded placebo-controlled manner to vaccine and control groups. The mean age was 48 years, with an almost equal number of males and females.

One group (A) received the two-dose homologous regimen, the second (group B) the heterologous three-dose regimen, and the third (group C) the placebo. None of the final participants had confirmed SARS-CoV-2 infection at any point.

There were 0.8 COVID-19 cases per 1,000 person-years (PY) in group A, and 2.7 in the placebo, corresponding to 198 and 155 cases, respectively, indicating a two-dose vaccine efficacy (VE) of 71% compared to placebo.

With the heterologous three-dose regimen, the VE was greater than 92% relative to the placebo, at an incidence of 0.1 per 1,000 PY in group B (170 vs 155 cases in groups B and C, respectively).

Protection against severe COVID-19 was 63% in group A and 100% for group B. Comparatively, when considering deaths due to COVID-19, VE was 59% and 100%, respectively.

Implications
The current study shows the SOBERANA 02 conjugate vaccine to be safe and effective in preventing severe COVID-19 in adults up to 80 years of age. A VE of over 60% was expected during the period when the ancestral SARS-CoV-2 strain was circulating. However, a VE of 62% was achieved, even during a period when the dominant strain was the Beta SARS-CoV-2 variant of concern (VOC).

The SARS-CoV-2 Beta strain made up 74% of isolated sequences at the time in Havana. The high VE was observed in spite of the presence of the E484K mutation that confers resistance to neutralizing antibodies in the sera of individuals who have been immunized by natural infection or by vaccination.

By the time the final analysis was conducted, the Delta VOC was the dominant circulating strain; however, the VE at two doses was 71% at this time. The heterologous three-dose regimen led to VE exceeding 92%, but it still remained high irrespective of VOCs in circulation.

Even at the two-month mark, the safety profile was impressive, with mild transient local reactions and no serious adverse reactions reported. The third dose of the vaccine had few side effects.

The final VE comes from the figures compiled 14 days after the last immunization, or 70 days after the first dose with the triple-dose regimen. While this vaccine apparently offered protection against the Beta and Delta VOCs, further work is essential to assess the durability of immunity and the VE for the circulating VOCs.

* Important notice
medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information
Comments

Oh ya 4 year ago
Well isn't that nice but i will just stick to natural ammunity thanks

Newsletter

Related Articles

0:00
0:00
Close
Severe Heatwave Claims 2,300 Lives Across Europe
NVIDIA Achieves Historic Milestone as First Company Valued at $4 Trillion
Declining Beer Consumption Signals Cultural Shift in Germany
Linda Yaccarino Steps Down as CEO of X After Two Years
US Imposes New Tariffs on Brazilian Exports Amid Political Tensions
Azerbaijan and Armenia are on the brink of a historic peace deal.
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Weinstein Victim’s Lawyer Says MeToo Movement Still Strong
U.S. Enacts Sweeping Tax and Spending Legislation Amid Trade Policy Shifts
Football Mourns as Diogo Jota and Brother André Silva Laid to Rest in Portugal
Labour Expected to Withdraw Support for Special Needs Funding Model
Leaked Audio Reveals Tory Aide Defending DEI Record
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
London Stock Exchange Faces Historic Low in Initial Public Offerings
A new online platform has emerged in the United Kingdom, specifically targeting Muslim men seeking virgin brides
Trump Celebrates Independence Day with B-2 Flyover and Signs Controversial Legislation
Boris Johnson Urges Conservatives to Ignore Farage
SNP Ordered to Update Single-Sex Space Guidance Within Days
Starmer Set to Reject Calls for Wealth Taxes
Stolen Century-Old Rolls-Royce Recovered After Hotel Theft
Macron Presses Starmer to Recognise Palestinian State
Labour Delayed Palestine Action Ban Over Riot Concerns
Swinney’s Tax Comments ‘Offensive to Scots’, Say Tories
High Street Retailers to Enforce Bans on Serial Shoplifters
Music Banned by Henry VIII to Be Performed After 500 Years
Steve Coogan Says Working Class Is Being ‘Ethnically Cleansed’
Home Office Admits Uncertainty Over Visa Overstayer Numbers
JD Vance Questions Mandelson Over Reform Party’s Rising Popularity
Macron to Receive Windsor Carriage Ride in Royal Gesture
Labour Accused of ‘Hammering’ Scots During First Year in Power
BBC Head of Music Stood Down Amid Bob Vylan Controversy
Corbyn Eyes Hard-Left Challenge to Starmer’s Leadership
London Tube Trains Suspended After Major Fire Erupts Nearby
Richard Kemp: I Felt Safer in Israel Under Attack Than in the UK
Cyclist Says Police Cited Human Rights Act for Riding No-Handed
China’s Central Bank Consults European Peers on Low-Rate Strategies
AI Raises Alarms Over Long-Term Job Security
Saudi Arabia Maintains Ties with Iran Despite Israel Conflict
Musk Battles to Protect Tesla Amid Trump Policy Threats
Air France-KLM Acquires Majority Stake in Scandinavian Airlines
UK Educators Sound Alarm on Declining Child Literacy
Shein Fined €40 Million in France Over Misleading Discounts
Brazil’s Lula Visits Kirchner During Argentina House Arrest
Trump Scores Legislative Win as House Passes Tax Reform Bill
Keir Starmer Faces Criticism After Rocky First Year in Power
DJI Launches Heavy-Duty Coaxial Quadcopter with 80 kg Lift Capacity
U.S. Senate Approves Major Legislation Dubbed the 'Big Beautiful Bill'
Largest Healthcare Fraud Takedown in U.S. History Announced by DOJ
×